Insider buying last 90 days
No open-market insider purchases were filed for OGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every OGN insider filing, plotted on the chart in Gekko.Open OGN in Gekko
Gekko Brief
AI summaryOct 12 closeOrganon touched a fresh 52-week high of $13.79 this week, extending a run that leaves the stock up 34.47% over the past year according to commentary accompanying the move, with the same coverage noting a view that the stock looks undervalued on a free cash flow basis. No other corporate, deal or regulatory news accompanied the move; the push to new highs appears to be the dominant story of the week.
OGN closed at $13.77, essentially flat on the day, sitting just above its 50-day average of $13.70 and well above its 200-day average of $11.09, consistent with an established uptrend. The GekkoIndex reads 51.8, placing the stock in the Neutral zone, down from a higher reading five days prior. Despite the trend, price remains 25.2% below the Gekko Fair Value estimate of $18.40.
Organon's next earnings report is scheduled for 9 November 2026, before the open, 27 days out and within a typical 20-trading-day holding window; the prior quarter saw EPS of $0.85 match estimates with a muted 0.1% reaction, though average absolute reactions have run near 7%. No insider, Congress or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a -11.4% move over five years, with gains in only 2 of those years, a pattern worth noting alongside the upcoming report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Organon price vs fair value
Close $13.77200-day averageGekko Fair Value $18.40
Organon quick facts
- Market cap
- $3.62B
- P/E ratio
- 17.6
- Forward P/E
- 5.1
- EPS, TTM
- $0.78
- Revenue, TTM
- $6.13B
- Profit margin
- 3.4%
- Dividend yield
- 0.58%
- Beta
- 1.54
- Volume
- 932,336 avg 2.12M
- 1-year return
- +38.8%
- Typical daily move
- ±0.3%
- Typical 20-day move
- ±8%
- 50-day average
- $13.70
- 200-day average
- $11.09
- Next earnings
- Nov 9 before open
- Shares outstanding
- 262.6M
Organon swing-trade checklist
Organon scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $13.77 is above the 50-day ($13.70) and 200-day ($11.09) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.8, Neutral
Reading 51.8 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
25.2% below
Price is 25.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−11.4% on average
From this point in the calendar, the next 20 trading days averaged −11.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Organon stock chart and price history
Organon closed at $13.77 on Oct 12, 2026, +38.8% over the past year, inside a 52-week range of $5.69 to $13.83.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.0%
- 3 months
- +2.0%
- 6 months
- +61.2%
- 1 year
- +38.8%
The full OGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open OGN in Gekko
Follow Organon through every session
Put OGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track OGN in GekkoFree for 7 days. No credit card required.
About Organon
Organon supplies a broad range of prescription medicines across several areas of medicine. Its women's health line covers contraception and fertility care, including the long-acting birth control product Nexplanon/Implanon, which the company is particularly associated with. Beyond this, Organon markets biosimilar treatments for immune conditions and certain cancers, along with established brands addressing heart health, respiratory conditions, allergies, skin disorders, bone density, pain management, prostate enlargement, and hair loss.
The company moves its medicines through wholesalers, pharmacies, hospitals and other medical sites, government bodies, and managed care organizations such as health maintenance organizations and pharmacy benefit managers. This network allows its products to reach patients across multiple therapeutic categories rather than through a single distribution channel.
Organon was founded in 2020 and operates out of Jersey City, New Jersey. Its shares trade on the NYSE under the ticker OGN.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- organon.com
Organon GekkoIndex: the smart money zone
Organon’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.8, in the Neutral zone, down 5.7 points over five sessions.
51.8Neutral
Down 5.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 65 | −0.2% | +8.4% | ||
| Accumulation | 214 | +0.9% | +3.4% | ||
| Neutral (current zone) | 362 | −0.2% | −1.8% | ||
| Distribution | 39 | +1.1% | +3.6% | ||
| Selling | 2 | Too few readings yet | |||
Average OGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the OGN price, zone by zone.Track OGN in Gekko
Is Organon stock overvalued? Gekko Fair Value
Organon trades 25.2% below Gekko Fair Value of $18.40, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Organon shares are worth, recalculated every trading day.
$18.40
Gekko Fair Value, Oct 10, 2026
25.2% Undervalued
At the end of Aug 2026 the price was 30.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open OGN in Gekko
Organon insider and Congress trading
No open-market insider purchases were filed for Organon, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in OGN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for OGN, plotted on the chart in Gekko.Open OGN in Gekko
Buybacks
Organon has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2025
- $1.00M
- As a share of market cap
- 0.03%
- Trailing four quarters
- $18.00M
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold OGN.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Organon earnings: next date and track record
Organon reports on Nov 9, 2026, before the open (28 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 28 days away
- EPS estimate
- $0.88
- Revenue estimate
- $1.58B
4 of 8reports beat the EPS estimate
±7%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 31, 2026 | $0.85 est $0.85 | $1.60B est $1.60B | +0.1% |
| Apr 30, 2026 | $0.71 est $0.85 | $1.46B est $1.49B | −0.4% |
| Feb 12, 2026 | $0.63 est $0.73 | $1.51B est $1.53B | −3.9% |
| Nov 10, 2025 | $1.01 est $0.93 | $1.60B est $1.52B | +10.9% |
| Aug 5, 2025 | $1.00 est $0.94 | $1.59B est $1.56B | −9.8% |
| May 1, 2025 | $1.02 est $0.89 | $1.51B est $1.54B | −25.8% |
| Feb 13, 2025 | $0.90 est $0.87 | $1.59B est $1.59B | +3.9% |
| Oct 31, 2024 | $0.87 est $0.90 | $1.58B est $1.56B | +0.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Organon stock forecast and analyst price targets
Analysts’ average 12-month price target for Organon is $11.25, −18.3% from the last close.
$11.25consensus 12-month target, −18.3% from the last close
−1.8%average 20-day move after past Neutral readings
−11.4%average move over the next 20 trading days in the last 5 years
±0.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Organon seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Organon averaged −11.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 2 of 5 |
| Next 10 trading days | −1.1% | 2 of 5 |
| Next 15 trading days | −4.5% | 2 of 5 |
| Next 20 trading days | −11.4% | 2 of 5 |
| Next 30 trading days | −16.0% | 1 of 5 |
For scale, OGN’s typical 20-trading-day move in either direction is about 8%.
Organon market cap and key statistics
Organon’s market cap is $3.62B, with a P/E ratio of 17.6 and revenue of $6.13B over the last twelve months.
Valuation
- Market cap
- $3.62B
- P/E ratio
- 17.6
- Forward P/E
- 5.1
- EPS, TTM
- $0.78
- Gekko Fair Value
- $18.40
Trading
- Volume
- 932,336
- Avg volume, 20 days
- 2.12M
- 52-week high
- $13.83
- 52-week low
- $5.69
- Shares outstanding
- 262.6M
Financials
- Revenue, TTM
- $6.13B
- Profit margin
- 3.4%
- Return on equity
- 24%
- Quarterly earnings growth, YoY
- −28.3%
Risk and income
- Beta
- 1.54
- Typical daily move
- ±0.3%
- Typical 20-day move
- ±8%
- Dividend yield
- 0.58%
Organon stock news this week
1 headline about Organon from the past week, newest first, each linking to the publisher.
- Organon & Co stock hits 52-week high at 13.79 USDInvesting.com, Oct 8
Organon peers
Organon’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Organon stock FAQ
What is Organon’s market cap?
Organon’s market cap is $3.62B at the Oct 12, 2026 close of $13.77, with 262.6M shares outstanding. The shares trade on a P/E ratio of 17.6.
What is the Organon stock forecast?
The consensus analyst 12-month price target for Organon is $11.25, −18.3% from the last close. Gekko doesn’t publish price predictions of its own.
Is Organon stock overvalued or undervalued?
On Gekko’s estimate Organon is undervalued: the Oct 12, 2026 close of $13.77 is 25.2% below Gekko Fair Value of $18.40. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Organon report earnings next?
Organon is expected to report on Nov 9, 2026, before the market opens (28 days away). Analysts expect earnings of $0.88 per share on revenue of $1.58B. Organon beat the earnings estimate in 4 of its last 8 reports, moving 7% on average across the report.
What is Organon’s 52-week high and low?
Organon’s 52-week high is $13.83 and its 52-week low is $5.69; it closed at $13.77 on Oct 12, 2026, +38.8% over the past year. Over the last five years the shares peaked at $39.48 on Mar 2, 2022.
Is Organon stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 1 as mixed (gekkoindex) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Organon the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.